ErikaHamiltonMD

Oncology • Nashville, TN

Physician

Join to view full profile

Dr. Hamilton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hamilton's full profile

Already have an account?

Office
250 25th Ave N
Suite 100
Nashville, TN 37203
Phone+1 615-320-5090

Fax+1 615-320-1225

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2013
University of North Carolina HospitalsResidency, Internal Medicine, 2007 - 2009
University of North Carolina at Chapel Hill School of MedicineClass of 2007

Certifications & Licensure

TN State Medical License 2013 - 2025
NC State Medical License 2007 - 2014
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
Completed
Phase 1
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
AZD9496 First Time in Patients Ascending Dose Study Start of enrollment: 2014 Oct 22
Completed
Phase 1
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors. Start of enrollment: 2015 Sep 23
Completed
Phase 1
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Start of enrollment: 2016 Jun 29
Completed
Phase 1
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
Completed
Phase 3
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
Completed
Phase 1
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Start of enrollment: 2021 Aug 09
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Start of enrollment: 2016 Nov 01
Recruiting
Phase 1
Roles: Contact
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
Roles: Contact, Principal Investigator
PRO1184 for Advanced Solid Tumors Start of enrollment: 2022 Dec 07
Recruiting
Phase 1, Phase 2
Roles: Contact
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Start of enrollment: 2023 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Sarina Piha-Paul, Shane A Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann
Clinical Cancer Research. 2025-01-17
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive
Nature Medicine. 2025-01-17
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.
Manish R Patel, Gerald S Falchook, Judy S Wang, Esteban Rodrigo Imedio, Sanjeev Kumar
Targeted Oncology. 2025-01-01

Lectures

The Metastatic Breast Cancer Project: Engaging Patients, Advancing Research
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC...
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
The Elusive Hunt for CDK Inhibitor Biomarkers
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Tox Check: Antibody Drug ConjugatesNovember 19th, 2024
More Younger Women and Asian Americans Are Getting Diagnosed with Breast CancerOctober 28th, 2024
Breast Cancer Awareness Month: Common Myths About the DiseaseOctober 13th, 2024
Join now to see all

ErikaHamiltonMD

Dr. Hamilton is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.